{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cytosorbents Corporation"},"Symbol":{"label":"Symbol","value":"CTSO"},"Address":{"label":"Address","value":"7 DEER PARK DRIVE,SUITE K, MONMOUTH JUNCTION, New Jersey, 08852, United States"},"Phone":{"label":"Phone","value":"+1 732 329-8885"},"Industry":{"label":"Industry","value":"Medical/Dental Instruments"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany."},"CompanyUrl":{"label":"Company Url","value":"https://www.cytosorbents.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Efthymios N. Deliargyris","title":"Chief Medical Officer"},{"name":"Phillip P. Chan","title":"Chief Executive Officer & Director"},{"name":"Steven Sisk","title":"Director-Clinical Operations"},{"name":"Vincent J. Capponi","title":"President & Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}